Risedronate with calcium carbonate and colecalciferol
Brand names: Actonel Combi
This is a combination osteoporosis product pairing the bisphosphonate risedronate with calcium carbonate and colecalciferol (vitamin D3), supplied so the bisphosphonate and the calcium/vitamin D component are taken on separate days.
We found no UK product information (SmPC) for this medicine or presentation on the eMC or MHRA Products (checked October 2026). It may be unlicensed in the UK, imported, a medical device, or no longer marketed. ClinCalc Pro shows only doses it can trace to official product information, so none is shown — follow your specialist service or local guideline.
Clinical monograph
How it works
Risedronate inhibits osteoclast-mediated bone resorption, while calcium and colecalciferol correct or prevent deficiency to support adequate substrate and calcium homeostasis for bone mineralisation.
Prescribing in practice
- Risedronate and the calcium-containing tablets must never be taken together, because calcium binds the bisphosphonate and abolishes its absorption; follow the calendar pack sequence exactly.
- Take risedronate on an empty stomach with plain water while sitting or standing upright, remaining upright afterwards to reduce oesophageal irritation and ulceration.
- Ensure adequate renal function and correct hypocalcaemia before starting; counsel on the rare risks of osteonecrosis of the jaw and atypical femoral fracture with prolonged use.
Monitoring
Monitor renal function and serum calcium, maintain dental health, and periodically review the continued need for bisphosphonate therapy.
Counselling the patient
- Follow the pack week by week and never take the risedronate tablet and the calcium tablets on the same day.
- Swallow risedronate whole with a full glass of water and stay sitting or standing for at least half an hour.
- Report any new thigh or groin pain, or dental problems, to your team.
Evidence & guidelines
Bisphosphonates reduce osteoporotic fracture risk, and combining with calcium and vitamin D reflects standard practice of ensuring adequate calcium and vitamin D status during antiresorptive therapy.
Reference: NICE TA464; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Hyperkalaemia Management Algorithm · Electrolyte Disorders
- FAST Exam Protocol — Focused Assessment with Sonography in Trauma · Trauma
- CAROC System — Fracture Risk Assessment · Osteoporosis
- FRAX Score (Fracture Risk Assessment) · Osteoporosis
- Corrected Calcium · Electrolytes
- Calcium-Phosphate Product · Electrolytes
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016